Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study ...

Having parents with a history of smoking is associated with a significantly increased risk of developing pediatric MS, a ...

For years, columnist Ben Hofmeister avoided talking about his invisible scars caused by the silent challenges of life with MS.

Researchers mapped myelin-making cells in mice, showing some brain regions recover better after myelin damage.

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and ...

Bladder issues are a daily reality for many with MS, writes columnist Desiree Lama, who encourages more open discussion about the topic.

A new community-led network called PRADA enables underrepresented patients living with MS to help set research priorities.

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...